Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim et al. · Diabetes Obesity and Metabolism · 2012 · 611 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 563 citations

Medicine, Cardiology, Pharmacology +15

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

Karin Rådholm, Gemma A. Figtree, Vlado Perkovic et al. · Circulation · 2018 · 487 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17